Spots Global Cancer Trial Database for autologous
Every month we try and update this database with for autologous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) | NCT00809588 | Melanoma | Autologous, let... | 18 Years - | Dana-Farber Cancer Institute | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) | NCT03795597 | Multiple Myelom... | Carfilzomib Busulfan IV Melphalan IV | 18 Years - | Loyola University | |
| Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) | NCT03795597 | Multiple Myelom... | Carfilzomib Busulfan IV Melphalan IV | 18 Years - | Loyola University | |
| Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | NCT02722941 | Multiple Myelom... | Panobinostat | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects | NCT02145130 | Burn Injury Soft Tissue Inj... Skin Necrosis Scars Congenital Gian... Skin Tumors | denovoDerm denovoSkin | 1 Year - 70 Years | University of Zurich | |
| Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. | NCT02006225 | Autologous Stem... | Plerixafor | - 30 Years | Tel-Aviv Sourasky Medical Center | |
| Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002844 | Leukemia | Cyclophosphamid... Allogeneic Bone... Autologous Bone... Total Body Irra... | 16 Years - 65 Years | M.D. Anderson Cancer Center | |
| Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects | NCT02145130 | Burn Injury Soft Tissue Inj... Skin Necrosis Scars Congenital Gian... Skin Tumors | denovoDerm denovoSkin | 1 Year - 70 Years | University of Zurich | |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | NCT01875653 | Stage IV Melano... Stage III Melan... | Autologous Dend... Autologous PBMC... | 18 Years - | Lisata Therapeutics, Inc. | |
| Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | NCT05066165 | Acute Myeloid L... | Arm 1: NTLA-500... Arm 2: NTLA-500... | 18 Years - | Intellia Therapeutics | |
| Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom | NCT00646750 | Non-Hodgkin's L... | Ybritumomab Tiu... | 18 Years - 70 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer | NCT00001193 | Breast Neoplasm... Neoplasm Metast... | high dose melph... | - | National Institutes of Health Clinical Center (CC) | |
| Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002844 | Leukemia | Cyclophosphamid... Allogeneic Bone... Autologous Bone... Total Body Irra... | 16 Years - 65 Years | M.D. Anderson Cancer Center | |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | NCT04844086 | B-cell Acute Ly... Non-Hodgkin's L... Non-Hodgkin's L... Primary Mediast... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... High-grade B-ce... | RPM CD19-mbIL15... | 20 Years - 75 Years | Eden BioCell Ltd. | |
| M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma | NCT00477906 | Melanoma | M-Vax- autologo... | - | AVAX Technologies | |
| Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS) | NCT01347034 | Soft Tissue Sar... | External Beam R... Autologous Dend... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer | NCT02662634 | Non-small Cell ... | AGS-003-LNG Carboplatin Abraxane Alimta Cisplatin Taxol Radiation Thera... | 19 Years - | GU Research Network, LLC | |
| Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | NCT00116467 | Acute Myelogeno... | GVAX leukemia v... | 18 Years - 60 Years | Cell Genesys | |
| Genetically Modified T Cells Against Ovarian Cancer | NCT03184753 | Ovarian Cancer | OC-IgT cells | 18 Years - 65 Years | Shenzhen Geno-Immune Medical Institute | |
| M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma | NCT00477906 | Melanoma | M-Vax- autologo... | - | AVAX Technologies | |
| Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | NCT00116467 | Acute Myelogeno... | GVAX leukemia v... | 18 Years - 60 Years | Cell Genesys | |
| Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. | NCT02006225 | Autologous Stem... | Plerixafor | - 30 Years | Tel-Aviv Sourasky Medical Center | |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03266692 | Multiple Myelom... Multiple Myelom... Refractory Mult... | ACTR087 SEA-BCMA | 18 Years - 80 Years | Cogent Biosciences, Inc. | |
| A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer | NCT00001193 | Breast Neoplasm... Neoplasm Metast... | high dose melph... | - | National Institutes of Health Clinical Center (CC) | |
| Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom | NCT00646750 | Non-Hodgkin's L... | Ybritumomab Tiu... | 18 Years - 70 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | NCT01548573 | Multiple Myelom... | Dexamethasone Tandem autologo... Cisplatin Doxorubicin Cyclophosphamid... Etoposide Bortezomib Thalidomide Melphalan | 18 Years - 80 Years | University of Iowa | |
| Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer | NCT02577588 | Colorectal Carc... | re-activated T ... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma | NCT01171092 | Malignant Lymph... Autologous Tran... | bortezomib and ... | 18 Years - | University of Kansas Medical Center | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma | NCT01171092 | Malignant Lymph... Autologous Tran... | bortezomib and ... | 18 Years - | University of Kansas Medical Center | |
| Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | NCT02703779 | Multiple Myelom... | Bortezomib Granulocyte col... Mozobil | 18 Years - | University of Kansas Medical Center | |
| Stem Cell Translpantation in Multiple Myeloma | NCT05082675 | Multiple Myelom... | HLA Matched all... | 18 Years - 70 Years | European Society for Blood and Marrow Transplantation | |
| Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma | NCT00257465 | Melanoma | Autologous, DNP... Autologous, DNP... Autologous, DNP... Autologous, DNP... Autologous, DNP... | 18 Years - | AVAX Technologies | |
| Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer | NCT00660101 | Adenocarcinoma ... | OVax: Autologou... | 18 Years - | AVAX Technologies | |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | NCT04596033 | Melanoma Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... Small-cell Lung... Cutaneous Squam... Anal Squamous C... Merkel Cell Car... | GEN-011 IL-2 Fludarabine Cyclophosphamid... | 18 Years - | Genocea Biosciences, Inc. | |
| Autologous Transplant for Multiple Myeloma | NCT00177047 | Multiple Myelom... | Stem Cell Trans... Cyclophosphamid... Melphalan Granulocyte-col... | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | NCT02722941 | Multiple Myelom... | Panobinostat | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma | NCT01946373 | Melanoma | Cyclophosphamid... Fludarabine T cells Interleukin-2 Dendritic cell ... | 18 Years - 74 Years | Karolinska University Hospital | |
| Stem Cell Translpantation in Multiple Myeloma | NCT05082675 | Multiple Myelom... | HLA Matched all... | 18 Years - 70 Years | European Society for Blood and Marrow Transplantation | |
| Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS) | NCT01347034 | Soft Tissue Sar... | External Beam R... Autologous Dend... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
